Schedule 13G ownership disclosure

Cumberland Pharmaceuticals, Inc.

Common Stock, no par value · CUSIP: 230770109

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Ikarian Capital, LLC

    Shares: 730,932 · Class: 4.9%

  • Neil Shahrestani

    Shares: 730,932 · Class: 4.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-072872
Form type
SCHEDULE 13G
Filer
CUMBERLAND PHARMACEUTICALS INC
CIK
CIK 1087294
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub